HCWB Valuation
HCW Biologics Inc
$
3.870
HCWB Relative Valuation
HCWB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, HCWB is overvalued; if below, it's undervalued.
Historical Valuation
HCW Biologics Inc (HCWB) is now in the Fair zone, suggesting that its current forward PS ratio of 3.87 is considered Fairly compared with the five-year average of -2.92. The fair price of HCW Biologics Inc (HCWB) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：3.87
Fair
-1.29
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
HCW Biologics Inc. (HCWB) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.87. The thresholds are as follows: Strongly Undervalued below -3.08, Undervalued between -3.08 and -1.97, Fairly Valued between 0.24 and -1.97, Overvalued between 0.24 and 1.35, and Strongly Overvalued above 1.35. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-1.41
EV/EBIT
HCW Biologics Inc. (HCWB) has a current EV/EBIT of -1.41. The 5-year average EV/EBIT is -3.13. The thresholds are as follows: Strongly Undervalued below -13.11, Undervalued between -13.11 and -8.12, Fairly Valued between 1.85 and -8.12, Overvalued between 1.85 and 6.84, and Strongly Overvalued above 6.84. The current Forward EV/EBIT of -1.41 falls within the Historic Trend Line -Fairly Valued range.
3.87
PS
HCW Biologics Inc. (HCWB) has a current PS of 3.87. The 5-year average PS is 262.12. The thresholds are as follows: Strongly Undervalued below -1505.75, Undervalued between -1505.75 and -621.81, Fairly Valued between 1146.06 and -621.81, Overvalued between 1146.06 and 2030.00, and Strongly Overvalued above 2030.00. The current Forward PS of 3.87 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
HCW Biologics Inc. (HCWB) has a current P/OCF of 0.00. The 5-year average P/OCF is -1.17. The thresholds are as follows: Strongly Undervalued below -7.65, Undervalued between -7.65 and -4.41, Fairly Valued between 2.08 and -4.41, Overvalued between 2.08 and 5.32, and Strongly Overvalued above 5.32. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
HCW Biologics Inc. (HCWB) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.40. The thresholds are as follows: Strongly Undervalued below -1.92, Undervalued between -1.92 and -1.16, Fairly Valued between 0.35 and -1.16, Overvalued between 0.35 and 1.11, and Strongly Overvalued above 1.11. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
HCW Biologics Inc (HCWB) has a current Price-to-Book (P/B) ratio of -159.84. Compared to its 3-year average P/B ratio of -19.86 , the current P/B ratio is approximately 704.80% higher. Relative to its 5-year average P/B ratio of -13.38, the current P/B ratio is about 1094.42% higher. HCW Biologics Inc (HCWB) has a Forward Free Cash Flow (FCF) yield of approximately -152.62%. Compared to its 3-year average FCF yield of -78.01%, the current FCF yield is approximately 95.64% lower. Relative to its 5-year average FCF yield of -58.18% , the current FCF yield is about 162.33% lower.
-159.84
P/B
Median3y
-19.86
Median5y
-13.38
-152.62
FCF Yield
Median3y
-78.01
Median5y
-58.18
Competitors Valuation Multiple
The average P/S ratio for HCWB's competitors is 2.06, providing a benchmark for relative valuation. HCW Biologics Inc Corp (HCWB) exhibits a P/S ratio of 3.87, which is 87.83% above the industry average. Given its robust revenue growth of -98.94%, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of HCWB decreased by 79.50% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -2.47K to -29.43K.
The secondary factor is the Revenue Growth, contributed -98.94%to the performance.
Overall, the performance of HCWB in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is HCW Biologics Inc (HCWB) currently overvalued or undervalued?
HCW Biologics Inc (HCWB) is now in the Fair zone, suggesting that its current forward PS ratio of 3.87 is considered Fairly compared with the five-year average of -2.92. The fair price of HCW Biologics Inc (HCWB) is between to according to relative valuation methord.
What is HCW Biologics Inc (HCWB) fair value?
How does HCWB's valuation metrics compare to the industry average?
What is the current P/B ratio for HCW Biologics Inc (HCWB) as of Nov 03 2025?
What is the current FCF Yield for HCW Biologics Inc (HCWB) as of Nov 03 2025?
What is the current Forward P/E ratio for HCW Biologics Inc (HCWB) as of Nov 03 2025?